Reducing the risk for suicide in schizophrenia and affective disorders.
Meltzer
Herbert Y
HY
Division of Psychopharmacology, Psychiatric Hospital, Vanderbilt University Medical Center, Nashville, Tenn, USA.
Baldessarini
Ross J
RJ
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D002423:Cause of Death; D003024:Clozapine / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D006801:Humans; D015994:Incidence; D015337:Multicenter Studies as Topic; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D012565:Schizophrenic Psychology; D013405:Suicide / Q000706:statistics & numerical data; D013406:Suicide, Attempted / Q000517:prevention & control / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D000092864:Suicide Prevention
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D000077152:Olanzapine